Indomethacin uptake into poly(2-hydroxyethyl methacrylate-co-3,9-divinyl-2,4,8,10-tetraoxaspiro [5.5]-undecane) network: In vitro and in vivo controlled release study.
Networks based on poly(2-hydroxyethyl methacrylate-co-3,9-divinyl-2,4,8,10-tetraoxaspiro [5.5]-undecane), synthesized through radical dispersion polymerization, were used as template for indomethacin (INN) as model drug. The copolymers were characterized by swelling studies at three pH values (2.4, 5.5 and 7.4) and two temperatures (room temperature 24 °C and physiological temperature 37 °C). Fourier transform infrared (FTIR) spectroscopic analysis was used to sustain the copolymer structures. Scanning electron microscopy (SEM) and thermogravimetric (TG) investigations were used to examine microstructure and appreciate the thermal stability of the polymer samples. The studies of the INN drug release from the copolymer networks were in vitro performed. The in vivo study results (biocompatibility tests, somatic nociceptive experimental model (tail flick test) and visceral nociceptive experimental model (writhing test)) are also reported in this paper.
"Petru Poni" Institute of Macromolecular Chemistry, Grigore Ghica Voda Alley No. 41-A, 700487 Iasi, Romania.
Loredana E
LE
Nita
"Petru Poni" Institute of Macromolecular Chemistry, Grigore Ghica Voda Alley No. 41-A, 700487 Iasi, Romania. Electronic address: achiriac1@yahoo.com.
Aurica P
AP
Chiriac
"Petru Poni" Institute of Macromolecular Chemistry, Grigore Ghica Voda Alley No. 41-A, 700487 Iasi, Romania.
Manuela T
MT
Nistor
Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Liliana
L
Tartau
D019342:Acetic Acid; D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004195:Disease Models, Animal; D004337:Drug Carriers; D004339:Drug Compounding; D006863:Hydrogen-Ion Concentration; D007213:Indomethacin / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D051379:Mice; D008855:Microscopy, Electron, Scanning; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D017288:Pain Threshold / Q000187:drug effects; D010316:Particle Size; D011108:Polymers / Q000737:chemistry*; D011109:Polymethacrylic Acids / Q000737:chemistry*; D011930:Reaction Time / Q000187:drug effects; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D013141:Spiro Compounds / Q000737:chemistry*; D013678:Technology, Pharmaceutical / Q000379:methods; D013696:Temperature; D013818:Thermogravimetry
D000700:Analgesics; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D011108:Polymers; D011109:Polymethacrylic Acids; D013141:Spiro Compounds; C572898:poly(2-hydroxyethyl methacrylate-co-3,9-divinyl-2,4,8,10-tetraoxaspiro(5.5)undecane); D019342:Acetic Acid; D007213:Indomethacin